



**Natco Pharma Limited**  
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 14, 2026

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

**Sub:** Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release regarding the receipt of approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India.

This is for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

Encl.: As above

**NATCO Pharma Ltd**

Natco House

Road No.2, Banjara Hills

Hyderabad-500 034, India

**NATCO receives approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India**

Hyderabad, India, February 14<sup>th</sup>, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") received approval for Semaglutide from CDSCO to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

**About NATCO Pharma Limited**

NATCO Pharma Limited, (NSE: NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's different manufacturing facilities are approved by several leading regulatory authorities like U.S. FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at [www.natcopharma.com](http://www.natcopharma.com).

**For further information or queries please contact:**

Rajeev Menon – Manager, Investor Relations

Email: [r.menon@natcopharma.co.in](mailto:r.menon@natcopharma.co.in)

Rajesh Chebiyam – EVP, Crop Health Sciences

Email: [investors@natcopharma.co.in](mailto:investors@natcopharma.co.in)

Tel: 040-23547532 / Ext – 323

**Follow us on:**X (formerly Twitter): [https://twitter.com/pharma\\_natco](https://twitter.com/pharma_natco)LinkedIn: <https://www.linkedin.com/company/natcopharma>